Pausing Arthritis Drugs Did Not Improve Vaccine Response
Stopping DMARDs before COVID-19 vaccination increased arthritis flare risks without boosting immunity.
Updated on Oct. 5, 2026 in Arthritis
Live Poll
Would you change your medication routine if it potentially made a vaccine more effective?
A clinical trial of 840 patients has found that temporarily holding targeted DMARDs prior to receiving a COVID-19 vaccine provides no benefit to antibody response. The study suggests that pausing these common immunosuppressants actually increases the risk of disease flares.
Why it matters
Patients with inflammatory arthritis often face uncertainty regarding the timing of their treatments around vaccinations. This trial provides evidence that interrupting standard medication regimens may cause unnecessary health complications without achieving better immune outcomes.
In a randomized trial of 840 patients with conditions including rheumatoid and psoriatic arthritis, researchers compared a 2-week hold of targeted DMARDs to continued treatment. The study found a geometric mean fold rise antibody ratio of 0.96, indicating no improvement in vaccine response for the hold arm.
The players
University of Alabama at Birmingham
An academic medical research institution where the lead researcher for this arthritis clinical trial is based.
The details
The trial assessed how immunosuppressive medications interact with the body's response to COVID-19 vaccination by measuring immunoglobulin G antibodies against the SARS-CoV-2 spike protein. While the strategy was intended to improve vaccine immunogenicity, data shows that 21.1% of patients in the hold group experienced a meaningful change in OMERACT flare scores, compared to 9.1% in the control arm. This suggests the biological benefit of medication adherence outweighs the potential for a minor immunological boost.
Timeline
Early 2021: COVID-19 vaccines were broadly launched.
Late 2021: Investigators began the COVER clinical trial.
2024: Data analysis began for the clinical trial.
Health Landscape
This study updates the established approach to managing immunosuppressive therapies during global vaccination rollouts. It moves the field away from precautionary medication holds that were widely debated when COVID-19 vaccines were first introduced.
If you are managing inflammatory arthritis with DMARDs, do not pause your medication for upcoming vaccines without consulting your physician first. This study highlights the importance of maintaining your treatment schedule to prevent disease flares, which occurred more frequently in patients who stopped their drugs.
The takeaway
Pausing medication can disrupt disease control without improving how well your body responds to a vaccine. Always have a specific conversation with your rheumatologist about the risks and benefits before altering your medication schedule for any vaccination.
Further reading
For more information on navigating treatment during immunizations, visit our Arthritis section.
Live Poll
Would you change your medication routine if it potentially made a vaccine more effective?
